Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules

Increasing evidence suggests that therapy targeting the human epidermal growth factor receptor 3 (HER3) could be a viable route for targeted cancer therapy. Here, we studied a novel drug conjugate, Z(HER3)-ABD-mcDM1, consisting of a HER3-targeting affibody molecule, coupled to the cytotoxic tubulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinne, Sara S., Yin, Wen, Borras, Anna Mestre, Abouzayed, Ayman, Leitao, Charles Dahlsson, Vorobyeva, Anzhelika, Löfblom, John, Ståhl, Stefan, Orlova, Anna, Gräslund, Torbjörn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219639/
https://www.ncbi.nlm.nih.gov/pubmed/35740315
http://dx.doi.org/10.3390/biomedicines10061293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219639/
https://www.ncbi.nlm.nih.gov/pubmed/35740315
http://dx.doi.org/10.3390/biomedicines10061293

Ejemplares similares